USA flag logo/image

An Official Website of the United States Government

THERAPY AGAINST RECALCITRANT C. albicans INFECTION

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88706
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AI074258
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ARIETIS
650 Albany St Boston, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: THERAPY AGAINST RECALCITRANT C. albicans INFECTION
Agency: HHS
Contract: 1R43AI074258-01A1
Award Amount: $599,243.00
 

Abstract:

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop an effective therapy against relapsing vaginosis caused by Candida albicans. The disease occurs in 8-9% of all women, and is recalcitrant to currently available therapies . Upon adherence to a surface, C. albicans forms persister cells which are tolerant to currently available antimicrobials. Known compounds alone are inactive against persisters, so we reasoned that a combination of a compound disabling persister formation with a conventional antifungal will lead to eradication of the infection. To test this hypothesis, we developed a screen for potentiators of miconazole, a standard therapy against vaginosis. A pilot screen of 5,000 compounds produced an early lead, AC9 tha t completely eradicates populations of C. albicans containing persisters in combination with miconazole. AC9 or miconazole alone have no activity against persisters. The Specific Aims of the project are: 1. In vitro validation of miconazole potenti ators. The pilot screen of 5,000 compounds for potentiators of miconazole against C. albicans persister-producing biofilms gave 13 confirmed hits, of which 1, AC9, showed considerable microbicidal activity in combination with miconazole, but not alone. Add itional hits will be obtained as described in Aim 2 below. The efficacy of potentiators in the presence of miconazole against a panel of C. albicans clinical isolates will be measured to determine MIC90 of the compound. Toxicity against human cells will be also examined. The probability of resistance development to the compound in the presence of miconazole will additionally be determined. Milestone: complete in vitro validation of AC9 and other lead compounds, which will indicate the feasibility of advanci ng these leads into animal studies at Phase II. 2. Identifying additional miconazole potentiators. a. Analogs of hit compounds. We will identify chemical analogs of AC9 and test them for potentiation of miconazole. Any compound with activity sup erior to AC9 will enter into validation. b. Screening for additional lead compounds. A compound library will be screened in a high-throughput format. As hits are identified, they, together with their available analogs, will enter the validation process described in Aim 1. Milestone: Identify ~10 potentiators of miconazole capable of eradicating a C. albicans biofilm and complete their in vitro validation. The proposed study will form the basis of a subsequent Phase II project, aimed at in vivo va lidation of the leads and their medicinal chemistry optimization. C. albicans is the major human fungal pathogen that forms essentially untreatable biofilm infections. This includes relapsing fungal vaginosis which afflicts 8-9% of all women and is recalcitrant to current therapies. This project will develop lead compounds that will form the basis for an effective therapeutic against vaginosis.

Principal Investigator:

Business Contact:


t.dahl@arietiscorp.com
Small Business Information at Submission:

ARIETIS
ARIETIS 650 Albany St BOSTON, MA 02118

EIN/Tax ID: 120524070
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No